Key Points

  • Daratumumab can achieve good results in advanced AL amyloidosis, but is less effective in nephrotic patients with high free light chains.

  • Translocation t(11;14) is beneficial, and myeloma-like hyperdiploidy is adverse for outcome with daratumumab therapy in AL.

Abstract

Daratumumab has shown promising first results in systemic amyloid light-chain (AL) amyloidosis. We analyzed a consecutive series of 168 patients with advanced AL receiving either daratumumab/dexamethasone (DD, n = 106) or daratumumab/bortezomib/dexamethasone (DVD, n = 62). DD achieved a remission rate (RR) of 64% and a very good hematologic remission (VGHR) rate of 48% after 3 months. Median hematologic event-free survival (hemEFS) was 11.8 months and median overall survival (OS) was 25.6 months. DVD achieved a 66% RR and a 55% VGHR rate. Median hemEFS was 19.1 months and median OS had not been reached. Cardiac organ responses were noted in 22% with DD and 26% with DVD after 6 months. Infectious complications were common (Common Terminology Criteria [CTC] grade 3/4: DD 16%, DVD 18%) and likely related to a high rate of lymphocytopenia (CTC grade 3/4: DD 20%, DVD 17%). On univariable analysis, hyperdiploidy and gain 1q21 conferred an adverse factor for OS and hemEFS with DD, whereas translocation t(11;14) was associated with a better hemEFS. N-terminal prohormone of brain natriuretic peptide >8500 ng/L could not be overcome for survival with each regimen. Multivariable Cox regression analysis revealed plasma cell dyscrasia (difference between serum free light chains [dFLC]) >180 mg/L as an overall strong negative prognostic factor. Additionally, nephrotic-range albuminuria with an albumin-to-creatinine-ratio (ACR) >220 mg/mmol was a significantly adverse factor for hemEFS (hazard ratio, 2.1 and 3.1) with DD and DVD. Daratumumab salvage therapy produced good results and remission rates challenging any therapy in advanced AL. Outcome is adversely influenced by the activity of the underlying plasma cell dyscrasia (dFLC) and nephrotic-range albuminuria (ACR).

REFERENCES

REFERENCES
1.
Lokhorst
HM
,
Plesner
T
,
Laubach
JP
, et al
.
Targeting CD38 with daratumumab monotherapy in multiple myeloma
.
N Engl J Med
.
2015
;
373
(
13
):
1207
-
1219
.
2.
Lonial
S
,
Weiss
BM
,
Usmani
SZ
, et al
.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
.
Lancet
.
2016
;
387
(
10027
):
1551
-
1560
.
3.
Sher
T
,
Fenton
B
,
Akhtar
A
,
Gertz
MA
.
First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis
.
Blood
.
2016
;
128
(
15
):
1987
-
1989
.
4.
Kaufman
GP
,
Schrier
SL
,
Lafayette
RA
,
Arai
S
,
Witteles
RM
,
Liedtke
M
.
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
.
Blood
.
2017
;
130
(
7
):
900
-
902
.
5.
Palumbo
A
,
Chanan-Khan
A
,
Weisel
K
, et al;
CASTOR Investigators
.
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
.
N Engl J Med
.
2016
;
375
(
8
):
754
-
766
.
6.
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis. https://clinicaltrials.gov/ct2/show/NCT03201965. Accessed 4 August 2019.
7.
Kumar
S
,
Dispenzieri
A
,
Lacy
MQ
, et al
.
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements
.
J Clin Oncol
.
2012
;
30
(
9
):
989
-
995
.
8.
Dittrich
T
,
Bochtler
T
,
Kimmich
C
, et al
.
AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis
.
Blood
.
2017
;
130
(
5
):
632
-
642
.
9.
Milani
P
,
Basset
M
,
Russo
F
,
Foli
A
,
Merlini
G
,
Palladini
G
.
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome
.
Blood
.
2017
;
130
(
5
):
625
-
631
.
10.
Wechalekar
AD
,
Schonland
SO
,
Kastritis
E
, et al
.
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
.
Blood
.
2013
;
121
(
17
):
3420
-
3427
.
11.
Hwa
YL
,
Gertz
MA
,
Kumar
SK
, et al
.
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis
.
Leukemia
.
2019
;
33
(
5
):
1268
-
1272
.
12.
Dittrich
T
,
Benner
A
,
Kimmich
C
, et al
.
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia
.
Haematologica
.
2019
;
104
(
7
):
1451
-
1459
.
13.
Bochtler
T
,
Hegenbart
U
,
Kunz
C
, et al
.
Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens
.
J Clin Oncol
.
2015
;
33
(
12
):
1371
-
1378
.
14.
Muchtar
E
,
Dispenzieri
A
,
Kumar
SK
, et al
.
Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
.
Leukemia
.
2017
;
31
(
7
):
1562
-
1569
.
15.
Ahn
YH
,
Kim
SH
,
Han
KH
, et al
.
Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea
.
Medicine (Baltimore)
.
2018
;
97
(
46
):
e13157
.
16.
Iqbal
SM
,
Stecklein
K
,
Sarow
J
,
Krabak
M
,
Hillengass
J
,
McCarthy
P
.
Elotuzumab in combination with lenalidomide and dexamethasone for treatment-resistant immunoglobulin light chain amyloidosis with multiple myeloma
.
Clin Lymphoma Myeloma Leuk
.
2019
;
19
(
1
):
e33
-
e36
.
17.
Bochtler
T
,
Hegenbart
U
,
Kunz
C
, et al
.
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study
.
Blood
.
2016
;
128
(
4
):
594
-
602
.
18.
Gertz
MA
,
Comenzo
R
,
Falk
RH
, et al
.
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004
.
Am J Hematol
.
2005
;
79
(
4
):
319
-
328
.
19.
Inker
LA
,
Astor
BC
,
Fox
CH
, et al
.
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD
.
Am J Kidney Dis
.
2014
;
63
(
5
):
713
-
735
.
20.
Palladini
G
,
Dispenzieri
A
,
Gertz
MA
, et al
.
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes
.
J Clin Oncol
.
2012
;
30
(
36
):
4541
-
4549
.
21.
Palladini
G
,
Hegenbart
U
,
Milani
P
, et al
.
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
.
Blood
.
2014
;
124
(
15
):
2325
-
2332
.
22.
Schemper
M
,
Smith
TL
.
A note on quantifying follow-up in studies of failure time
.
Control Clin Trials
.
1996
;
17
(
4
):
343
-
346
.
23.
Grambsch
P
,
Therneau
T
.
Proportional hazards tests and diagnostics based on weighted residuals
.
Biometrika
.
1994
;
81
(
3
):
515
-
526
.
24.
National Cancer Institute
. Common Terminology Criteria for Adverse Events (CTCAE). Protocol development. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 7 August 2019.
25.
Usmani
SZ
,
Weiss
BM
,
Plesner
T
, et al
.
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
.
Blood
.
2016
;
128
(
1
):
37
-
44
.
26.
de Larrea
CF
,
Rodríguez-Lobato
LG
,
Tovar
N
, et al
.
Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome [abstract]
.
Blood
.
2017
;
130
(
suppl 1
). Abstract
5365
.
27.
Counsilman
CE
,
Jol-van der Zijde
CM
,
Stevens
J
,
Cransberg
K
,
Bredius
RG
,
Sukhai
RN
.
Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome
.
Pediatr Nephrol
.
2015
;
30
(
8
):
1367
-
1370
.
28.
Jacobs
R
,
Langer-Jacobus
T
,
Duong
M
, et al
.
Detection and quantification of rituximab in the human urine
.
J Immunol Methods
.
2017
;
451
:
118
-
121
.
29.
Xu
XS
,
Yan
X
,
Puchalski
T
, et al
.
Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma
.
Clin Pharmacol Ther
.
2017
;
101
(
6
):
721
-
724
.
30.
Sachchithanantham
S
,
Roussel
M
,
Palladini
G
, et al
.
European Collaborative Study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin M-related light chain amyloidosis
.
J Clin Oncol
.
2016
;
34
(
17
):
2037
-
2045
.
31.
Bochtler
T
,
Merz
M
,
Hielscher
T
, et al
.
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma
.
Blood Adv
.
2018
;
2
(
20
):
2607
-
2618
.
32.
Seckinger
A
,
Hillengass
J
,
Emde
M
, et al
.
CD38 as immunotherapeutic target in light chain amyloidosis and multiple myeloma-association with molecular entities, risk, survival, and mechanisms of upfront resistance
.
Front Immunol
.
2018
;
9
:
1676
.
33.
Kriegsmann
K
,
Dittrich
T
,
Neuber
B
, et al
.
Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma
.
Cytometry B Clin Cytom
.
2018
;
94
(
5
):
611
-
620
.
34.
Nijhof
IS
,
Casneuf
T
,
van Velzen
J
, et al
.
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
.
Blood
.
2016
;
128
(
7
):
959
-
970
.
35.
Bochtler
T
,
Hegenbart
U
,
Kunz
C
, et al
.
Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone
.
Amyloid
.
2014
;
21
(
1
):
9
-
17
.
36.
Abeykoon
JP
,
Zanwar
S
,
Dispenzieri
A
, et al
.
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis
.
Leukemia
.
2019
;
33
(
2
):
531
-
536
.
37.
Manwani
R
,
Cohen
O
,
Sharpley
F
, et al
.
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib
.
Blood
.
2019
;
134
(
25
):
2271
-
2280
.
38.
Jaccard
A
,
Comenzo
RL
,
Hari
P
, et al
.
Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)
.
Haematologica
.
2014
;
99
(
9
):
1479
-
1485
.
39.
Palladini
G
,
Milani
P
,
Foli
A
, et al
.
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients
.
Leukemia
.
2014
;
28
(
12
):
2311
-
2316
.
40.
Sanchorawala
V
,
Wright
DG
,
Rosenzweig
M
, et al
.
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
.
Blood
.
2007
;
109
(
2
):
492
-
496
.
41.
Kumar
SK
,
Hayman
SR
,
Buadi
FK
, et al
.
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial
.
Blood
.
2012
;
119
(
21
):
4860
-
4867
.
42.
Dispenzieri
A
,
Buadi
F
,
Laumann
K
, et al
.
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
.
Blood
.
2012
;
119
(
23
):
5397
-
5404
.
43.
Palladini
G
,
Milani
P
,
Foli
A
, et al
.
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis
.
Blood
.
2017
;
129
(
15
):
2120
-
2123
.
44.
Ponikowski
P
,
Voors
AA
,
Anker
SD
, et al;
ESC Scientific Document Group
.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
.
Eur Heart J
.
2016
;
37
(
27
):
2129
-
2200
.
45.
Van de Wyngaert
Z
,
Carpentier
B
,
Pascal
L
, et al
.
Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population
.
Br J Haematol
.
2020
;
188
(
3
):
e24
-
e27
.
46.
Mateos
M-V
,
Dimopoulos
MA
,
Cavo
M
, et al;
ALCYONE Trial Investigators
.
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
.
N Engl J Med
.
2018
;
378
(
6
):
518
-
528
.
47.
Fermand
J-P
,
Bridoux
F
,
Kyle
RA
, et al;
International Kidney and Monoclonal Gammopathy Research Group
.
How I treat monoclonal gammopathy of renal significance (MGRS)
.
Blood
.
2013
;
122
(
22
):
3583
-
3590
.
You do not currently have access to this content.

Sign in via your Institution

Sign In